Cargando…
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study
PURPOSE: To compare the effectiveness and safety of a drug in daily practice with the outcomes of a target non‐inferiority trial by rigorously mimickingin an observational study the trial's design features. METHODS: This cohort study was conducted using the British Clinical Practice Research Da...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687233/ https://www.ncbi.nlm.nih.gov/pubmed/32537897 http://dx.doi.org/10.1002/pds.5065 |
_version_ | 1783613486926921728 |
---|---|
author | Althunian, Turki A. de Boer, Anthonius Groenwold, Rolf H. H. Rengerink, Katrien O. Souverein, Patrick C. Klungel, Olaf H. |
author_facet | Althunian, Turki A. de Boer, Anthonius Groenwold, Rolf H. H. Rengerink, Katrien O. Souverein, Patrick C. Klungel, Olaf H. |
author_sort | Althunian, Turki A. |
collection | PubMed |
description | PURPOSE: To compare the effectiveness and safety of a drug in daily practice with the outcomes of a target non‐inferiority trial by rigorously mimickingin an observational study the trial's design features. METHODS: This cohort study was conducted using the British Clinical Practice Research Datalink (CPRD) to emulate the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial. Patients with atrial fibrillation who were newly prescribed (>=12 months of no use) either rivaroxaban or warfarinfrom October 2008 to December 2017 were included. Non‐inferiority of rivaroxaban to warfarin in the prevention of stroke or systemic embolism was assessed in different analysis populations (intention‐to‐treat [ITT], per‐protocol [PP], and as‐treated populations) using a hazardratio (HR) of 1.46 as the non‐inferiority margin. Major bleeding (safety outcome) was also assessed and compared to that of the target trial. All outcomes were analyzed using Cox‐proportional hazard analyses. RESULTS: We included 25,473 incident users of rivaroxaban (n=4,008) or warfarin(n=21,465). Similar to the trial, non‐inferiority in the primary out come was demonstrated in all three analysis populations: HR=1.04 (95%CI 0.84 to 1.30) (ITT), HR=0.98 (95%CI 0.70 to 1.38) (PP), and HR=1.11 (95%CI 0.86 to 1.42) (as‐treated). Risk of major bleeding was also similar to the target trial. CONCLUSION: The results of this study provide supportive evidence to the effectiveness of rivaroxaban and adds knowledge on the usefulness of emulating a non‐inferiority trial to assess drug effectiveness. |
format | Online Article Text |
id | pubmed-7687233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76872332020-12-05 Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study Althunian, Turki A. de Boer, Anthonius Groenwold, Rolf H. H. Rengerink, Katrien O. Souverein, Patrick C. Klungel, Olaf H. Pharmacoepidemiol Drug Saf Original Reports PURPOSE: To compare the effectiveness and safety of a drug in daily practice with the outcomes of a target non‐inferiority trial by rigorously mimickingin an observational study the trial's design features. METHODS: This cohort study was conducted using the British Clinical Practice Research Datalink (CPRD) to emulate the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial. Patients with atrial fibrillation who were newly prescribed (>=12 months of no use) either rivaroxaban or warfarinfrom October 2008 to December 2017 were included. Non‐inferiority of rivaroxaban to warfarin in the prevention of stroke or systemic embolism was assessed in different analysis populations (intention‐to‐treat [ITT], per‐protocol [PP], and as‐treated populations) using a hazardratio (HR) of 1.46 as the non‐inferiority margin. Major bleeding (safety outcome) was also assessed and compared to that of the target trial. All outcomes were analyzed using Cox‐proportional hazard analyses. RESULTS: We included 25,473 incident users of rivaroxaban (n=4,008) or warfarin(n=21,465). Similar to the trial, non‐inferiority in the primary out come was demonstrated in all three analysis populations: HR=1.04 (95%CI 0.84 to 1.30) (ITT), HR=0.98 (95%CI 0.70 to 1.38) (PP), and HR=1.11 (95%CI 0.86 to 1.42) (as‐treated). Risk of major bleeding was also similar to the target trial. CONCLUSION: The results of this study provide supportive evidence to the effectiveness of rivaroxaban and adds knowledge on the usefulness of emulating a non‐inferiority trial to assess drug effectiveness. John Wiley & Sons, Inc. 2020-06-14 2020-10 /pmc/articles/PMC7687233/ /pubmed/32537897 http://dx.doi.org/10.1002/pds.5065 Text en © 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Reports Althunian, Turki A. de Boer, Anthonius Groenwold, Rolf H. H. Rengerink, Katrien O. Souverein, Patrick C. Klungel, Olaf H. Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study |
title | Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study |
title_full | Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study |
title_fullStr | Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study |
title_full_unstemmed | Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study |
title_short | Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study |
title_sort | rivaroxaban was found to be noninferior to warfarin in routine clinical care: a retrospective noninferiority cohort replication study |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687233/ https://www.ncbi.nlm.nih.gov/pubmed/32537897 http://dx.doi.org/10.1002/pds.5065 |
work_keys_str_mv | AT althunianturkia rivaroxabanwasfoundtobenoninferiortowarfarininroutineclinicalcarearetrospectivenoninferioritycohortreplicationstudy AT deboeranthonius rivaroxabanwasfoundtobenoninferiortowarfarininroutineclinicalcarearetrospectivenoninferioritycohortreplicationstudy AT groenwoldrolfhh rivaroxabanwasfoundtobenoninferiortowarfarininroutineclinicalcarearetrospectivenoninferioritycohortreplicationstudy AT rengerinkkatrieno rivaroxabanwasfoundtobenoninferiortowarfarininroutineclinicalcarearetrospectivenoninferioritycohortreplicationstudy AT souvereinpatrickc rivaroxabanwasfoundtobenoninferiortowarfarininroutineclinicalcarearetrospectivenoninferioritycohortreplicationstudy AT klungelolafh rivaroxabanwasfoundtobenoninferiortowarfarininroutineclinicalcarearetrospectivenoninferioritycohortreplicationstudy |